Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Neotope Biosciences

- PMLiVE

Mylan swoops in on Perrigo with $30bn offer

Comes amid a swarm of deals for both companies in recent years

- PMLiVE

2013 – biotech boomed

The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines

- PMLiVE

Perrigo agrees $8.6bn deal to buy Elan

Ends months of speculation about fate of Irish pharma company

- PMLiVE

FDA fast-tracks Elan’s Alzheimer’s drug

Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms

- PMLiVE

Elan blocks Royalty takeover – for now

After rejecting Royalty Pharma's bid Elan wants greater clarity on the deal

- PMLiVE

Royalty Pharma raises Elan bid as deals keep coming

Values Elan at about $6.5bn

- PMLiVE

Elan buys into GSK-partnered Theravance programmes for $1bn

Takes a royalty interest in four respiratory drugs

- PMLiVE

Royalty Pharma sweetens bid for Elan

Says new offer places $4.4bn value on Tysabri royalties

- PMLiVE

Royalty Pharma mulls bid for Elan

Follows Biogen’s $3.25bn acquisition of Tysabri from Elan

- PMLiVE

Biogen gains full rights to Tysabri in $3.25bn deal with Elan

Ends decade-long partnership for MS drug

- PMLiVE

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

Elan spins out research business

Drug discovery operations will form a new stand-alone company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links